RecruitingPhase 2NCT06924606

Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy

A Phase II Study of JS207 (PD-1/VEGF Dual Antibody) in Combination With or Without JS004 or Docetaxel in Advanced Non-small Cell Lung Cancer With Disease Progression During or After the Treatment of Platinum-based Chemotherapy and Immunotherapy

Sponsor

Shanghai Junshi Bioscience Co., Ltd.

Enrollment

66 participants

Start Date

Jul 15, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced NSCLC

Summary

This is a multiple-arm, open phase II clinical trial evaluating the safety, tolerability,and preliminary efficacy of JS207 in NSCLC after progression following Platinum-based chemotherapy and immunotherapy.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called JS207 in patients with advanced non-small cell lung cancer (NSCLC) whose cancer progressed after receiving both immunotherapy (PD-1/PD-L1 inhibitors) and platinum-based chemotherapy. **You may be eligible if...** - You have locally advanced (stage IIIB/IIIC), metastatic, or recurrent NSCLC confirmed by biopsy - Your cancer progressed after receiving a PD-1/PD-L1 inhibitor plus platinum chemotherapy as first-line treatment, or after sequential first- and second-line treatment - You have at least one measurable tumour on scans - Your general health is adequate (organ function tests will confirm) **You may NOT be eligible if...** - Your cancer contains neuroendocrine components (a different subtype) - You have EGFR, ALK, ROS1, or other driver gene mutations with approved targeted treatments available - You have active brain metastases or serious autoimmune conditions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGJS207 injection +docetaxel

Patients receive JS207 10mg/kg or other dosage and docetaxel 75mg/m2, q3w.

DRUGJS207 injection +JS004 injection

Patients receive JS207 10mg/kg or other dosage and JS004 200mg, q3w.

DRUGJS207 injection

Patients receive JS207 10mg/kg or other dosage.

Locations(18)

Beijing Chest Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Jilin Cancer Hospital

Jilin, Changchun, China

Hunan Cancer Hospital

Hunan, Changsha, China

West China Hospital, Sichuan University

Sichuan, Chengdu, China

Second Affiliated Hospital, PLA Academy of Military Medical Sciences

Chongqing, Chongqing Municipality, China

Army Medical Center, PLA

Chongqing, Chongqing Municipality, China

The First Affiliated Hospital of Guangzhou Medical University

Guangdong, Guangzhou, China

Harbin Medical University Cancer Hospital

Heilongjiang, Harbin, China

Anyang Tumor Hospital

Anyang, Henan, China

The First Affiliated Hospital of Henan University of Science and Technology

Luoyang, Henan, China

The First Affiliated Hospital of Xinxiang Medical University

Xinxiang, Henan, China

The First People's Hospital of Changde

Changde, Hunan, China

The First Affiliated Hospital of Nanchang University

Jiangxi, Nanchang, China

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China

The Third People's Hospital of Datong

Datong, Shanxi, China

Yibin Second People's Hospital

Yibin, Sichuan, China

Affiliated Tumor Hospital of Xinjiang Medical University

Xinjiang, Xinjiang, China

Shanghai Pulmonary Hospital

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06924606

Related Trials

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

NCT021331961 location

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

NCT05609578166 locations

A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor

NCT0675855714 locations

Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

NCT067520572 locations

Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment

NCT067520442 locations